Next-Generation Adjuvants

Adjuvance Technologies’ adjuvants build on the proven effectiveness of saponin adjuvants and are designed to provide potent immunostimulation and favorable tolerability with scalable, sustainable, and efficient manufacturing.

Our lead candidate is the semi-synthetic saponin adjuvant TQL-1055, an analogue of the QS-21 adjuvant. We are developing a pipeline of rationally designed saponin adjuvants and combination adjuvants. Each adjuvant and combination offer specific advantages and uses.

Rational Adjuvant Design

Adjuvance has retained the desirable properties of, and eliminated several challenges with, the QS-21 adjuvant.  A fundamental benefit is that TQL-1055 is a semi-synthetic molecule starting with a natural triterpene core and using controlled structural modifications at the molecular level for completion.  TQL-1055 synthesis uses raw material from leaves and branches of the Quillaja saponaria tree, making its harvest sustainable and available in greater quantities than the source material for other saponin adjuvants.  The structural modifications to TQL-1055 allow Adjuvance to:

  • Eliminate a section of QS-21 which has been associated with adverse events
  • Substitute a stronger chemical bond, making TQL-1055 more stable than QS-21
  • Simplify two sections of TQL-1055 making the synthesis more efficient

Our Competitive Advantage

TQL-1055 is anticipated to have many advantages as a vaccine adjuvant including potent immunostimulatory properties, improved tolerability compared with other saponin adjuvants, and scalable, sustainable, and efficient manufacturing.


Other saponins

TQL-1055

Adjuvanticity

Excellent

Excellent

Tolerability

Poor

Improved

Source materials

Limited

Expanded

Yield

Low

Increased

Purity

Mixed

High

Stability

Limited

Increased

Manufacturing efficiency

Low

Increased

Doses per year

?

~3B

Regulatory

Accepted

Phase 1 clinical trial

Our Combination Adjuvants

Building from the foundation of TQL-1055, we are advancing combination adjuvants which are each designed to evoke specific types of immune responses and for use in different therapeutic areas.

Commercial Petussis with 1055